{
  "docId": "019de077-03c2-7682-9c49-749c55840a7d",
  "docSlug": "7d4a71c8904800c2c7c70f8e07dfcf66",
  "documentTitle": "Exscientia | Results Presentation Deck | 22 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 22,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard clinical trial progression from dose escalation to expansion, with specific patient enrollment targets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-03c2-7682-9c49-749c55840a7d/15",
  "deckHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d",
  "deckJsonHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d.json",
  "deckAnchorHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.42,
        "w": 0.67,
        "x": 0.24,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Two-part trial design flow from Part 1 (Dose Escalation) to Part 2 (Dose Expansion) via RP2D",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dbeadf2-07fc-4ee8-89d4-07bd2bfc40b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours (who have failed on, refused or are ineligible for the standard of care (SoC))",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdcd479e-9591-45ef-87f5-1af99cb181c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "486879f6-4674-4786-a383-3fee6486da38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf985cdb-6831-41b8-a2f5-c638f702fea0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a8069c4-e28b-4d3b-9751-f165e9b1115e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "ef98721f-01f0-4b6a-9f93-35c5d24e861e",
      "evidence": "The slide structure follows a standard clinical trial protocol layout (Phase 1/2, dose escalation/expansion).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 13,
      "beatId": "ac22c057-1c2d-4a7e-9615-3a68519957b2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck showcases pipeline updates and proposed solutions",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 13,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "59bbe9a5-4dee-402a-a171-3cbe1ef4dc26",
      "evidence": "The deck presents a logic chain with pipeline updates and proposed solutions",
      "position": 1,
      "objective": "How does Exscientia's pipeline support its growth strategy?",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.6,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}